Abstract
With great interest we have read the manuscript written by Murthy et al, published in Gut in June 2019, on the influence of anti-tumour necrosis factor alpha (TNFα) therapy introduction on the rate of hospitalisation and intestinal resection rates in IBD. 1 Despite the difference in the source of data between both studies (Canada: health administrative data and the Netherlands: nationwide pathology database), a declining rate of intestinal resections in Crohn's disease has been confirmed in Canada, at equal rates as the decline that has been observed in the Netherlands. 2 The authors used an advanced statistical method to analyse the impact of anti-TNFα introduction on (among other end points) the rate of intestinal resection. However, in our opinion, the hypothesised direct relationship between introduction of anti-TNFα and a decline in intestinal resection rate is vastly oversimplified for two important reasons. First, several other factors that have influenced both (early) diagnosis and management of Crohn's disease should be taken into account. Important changes over the past decades include improved access to endoscopy, less complications at diagnosis and development of strict and non-invasive monitoring strategies. In their original hypothesis, the authors also state the expectation that